Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in two virtual fireside chats at upcoming healthcare conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in two virtual fireside chats at upcoming healthcare conferences. The Cowen 42nd Annual Health Care Conference is scheduled for March 9, 2022, at 9:10 am ET, followed by the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 2:00 pm ET. Interested parties can access the live webcasts on Protara's website, where they will remain archived for 90 days. Protara focuses on innovative therapies for cancer and rare diseases, including its lead program TARA-002.
Details
News Market Reaction – TARA
The recorded move for TARA in the trading session of this news was +6.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual conferences:
- Cowen 42nd Annual Health Care Conference on March 9, 2022 at 9:10am ET
- Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022 at 2:00pm ET
A live webcast of the fireside chats can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived on the Company’s website for 90 days following the presentations.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.